Another BACE1 inhibitor is (R)-6-[(1,1′-biphenyl)-4-ylmethoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-2-naphthalene-ethan-amine hydrochloride monohydrate (TAK-070), which is a non-peptidic agent and reduces the expression levels of soluble Aβ, blocks the cerebral accumulation of insoluble Aβ, enhances neurotrophic APP and reduces behavioral problems in AD transgenic mouse models [54]. This evidence concerns the gene APP and Alzheimer disease.